Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11.

PURPOSE: For the 10% of women diagnosed with cancer within reproductive age, reproductive health is a critical component of oncologic survivorship. Variable attention to guidelines pertaining to oncocontraception and oncofertility results in cancer care discordant with a patient's reproductive health goals, negatively affecting quality of life. This study aimed to determine if the Engendering Reproductive Health within Oncologic Survivorship (EROS) multilevel intervention improves reproductive health goal-concordant management within 3 months of cancer diagnosis. PATIENTS AND METHODS: EROS is a cluster randomized trial, with 17 US-based National Cancer Institute Community Oncology Research Program (NCORP) sites (including Minority/Underserved Sites) randomly assigned to receive either reproductive health intervention (RHI; eight sites) or standard of care (SC; nine sites). Eligible patients included patients age 15-55 years with a new cancer diagnosis. The multilevel intervention included reproductive health education and navigation components. The primary study outcome is reproductive health goal-concordant management. CONCLUSION: The EROS intervention demonstrated marked improvement of reproductive health goal-concordant care, especially among patients who had completed childbearing. The multilevel EROS intervention demonstrates promise to improve adherence to national cancer guidelines at the complex intersection of reproductive health and cancer survivorship.